Meeting The Needs Of Under-Served Patients
At Adare Pharma Solutions, our vision is to create innovative dosage forms that can dramatically improve the quality of life for patients. We never forget that a pharma company has an obligation to overcome any challenges and serve all patients.
Our Patient Centered Solutions help us fulfill this promise. By leveraging our decades of experience, our teams of dosage form experts have created technologies that help ensure compliance in specific patient populations that are often overlooked in the marketplace.
For example, dysphagic patients. Dysphagia is difficulty swallowing, and it often occurs in the very young and the elderly, as well as from a variety of diseases including stroke, multiple sclerosis, and cancers of the throat. It’s estimated that 1 in 17 people will develop dysphagia in their lifetime.
Adare has developed dosage form technologies that allow drug products to be easier to swallow, using techniques like multi-state changing solutions and orally disintegrated tablets. Just another way that Adare Pharma Services is helping to serve the full spectrum of patients.
Parvulet is an oral solid dosage form that is ideal for pediatric and geriatric populations, as well as patients with swallowing difficulties.
Parvulet pills are solid dosage forms until soak in a spoonful of water for 30 seconds, during which time they dissolve into a final texture similar to that of apple sauce.
- Easily administered in 30 seconds
- Swallowing aid built into formulation
- Mimics natural swallowing mechanism with no choking hazards
AdvaTab Advanced ODT technology provides easy ingestion for pediatric, geriatric, and dysphagic patients.
Composed of finely micronized particles that rapidly disperse into a smooth and viscous suspension, AdvaTab is an easy-to-take dosage solution.
- Masks bitter drug taste
- Rapidly dissolves in the mouth
- No need for water
Speak With An Expert
Director, Drug Product Development
Nathan Dormer, Ph.D., is the Director of Drug Product Development at Adare Pharma Solutions and is responsible for pharmaceutical development activities at Adare’s Lenexa, KS site where he supports a team of formulation scientists and analysts. He is a pharmaceutical scientist and bioengineer by training, with more than 16 years of experience developing microsphere-based solid oral and parenteral/implantable dosage forms in academic, innovator, and CDMO settings. Dr. Dormer earned his B.S. in Chemical Engineering and his Ph.D. (w/Honors) in Bioengineering from The University of Kansas while receiving NIH-sponsored Pharmaceutical Biotech Training.